Eli Lilly to Acquire AtaiBeckley for $6.75/Share Cash Plus Up to $2.50 in CVRs
ATAI has more than doubled off its 52-week low of $2.58.
Summary
Eli Lilly will acquire AtaiBeckley for $6.75 per share in cash plus up to $2.50 per share in contingent value rights, a total potential value of $9.25 per share. The deal values AtaiBeckley at approximately $2.8 billion upfront and is expected to close in Q3 2026.
Key Events · M&A and Partnerships · ATAI
-
Acquisition by Eli Lilly
Eli Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash at closing, plus one contingent value right (CVR) per share worth up to $2.50 upon achievement of specified milestones.
-
Total Deal Value
The upfront cash consideration represents an aggregate equity value of approximately $2.8 billion. The CVRs could add up to $1.0 billion in additional payments, for a total potential value of $9.25 per share.
-
CVR Milestones
CVR payments: $1.00/share upon Phase 3 initiation of VLS-01 (by 4th anniversary of closing); $0.50/share upon U.S. approval and DEA rescheduling of BPL-003 (by 5th anniversary); $1.00/share upon U.S. approval and DEA rescheduling of VLS-01 (by 7th anniversary).
-
Shareholder Support
Apeiron Investment Group and all directors and officers, holding approximately 15% of outstanding shares, have signed voting agreements to support the transaction.
Analysis · ATAI · Life Sciences
In a deal that reshapes the neuroplastogen landscape, Eli Lilly is acquiring AtaiBeckley for approximately $2.8 billion upfront, with an additional $1.0 billion in potential milestone payments via contingent value rights. The $6.75 per share cash offer represents a roughly 40% premium to the 30-day VWAP. The acquisition brings Lilly a late-stage pipeline for treatment-resistant depression, including BPL-003, which has Breakthrough Therapy Designation and has initiated Phase 3. The deal is expected to close in Q3 2026, subject to stockholder and regulatory approvals. This is a thesis-altering event that will likely reprice the stock near the deal value.
At the time of this filing, ATAI was trading at $7.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.58 to $6.75. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.